Consensus Gilead Sciences, Inc.

Stocks

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-10-16 EDT			5-day change	1st Jan Change
156.19 ^USD	-0.75%		+3.32%	+27.25%

10-16	Gilead Sciences Insider Sold Shares Worth $468,660, According to a Recent SEC Filing	MT
10-16	Gilead Sciences Insider Sold Shares Worth $468,660, According to a Recent SEC Filing	MT

Evolution of the Average Target: Gilead Sciences, Inc.

Evolution of the Target Price: Gilead Sciences, Inc.

Changes in Analyst Recommendations: Gilead Sciences, Inc.

2d771.ZPEem5-WBLagsGRqPyZb_9P9AF7KJDBZtDxF086XycU.KpR89PTDZeXMhlADSlQeyL-2TzCpSnsbjFJomYTNqpQPsnHx8MVq_Pf8LQ~08c9243633df637b16bf82e1fcd68547

Analysts' recommendations: Gilead Sciences, Inc.

10-15	Goldman Sachs Adjusts Price Target on Gilead Sciences to $142 From $135	MT
10-12	Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says	MT
10-12	BofA Securities Adjusts Gilead Sciences Price Target to $168 From $162, Maintains Buy Rating	MT
10-08	RBC Lifts Price Target on Gilead Sciences to $126 From $123, Keeps Sector Perform Rating	MT
10-07	Morgan Stanley Adjusts Price Target on Gilead Sciences to $163 From $165	MT
10-07	JPMorgan Adjusts Price Target on Gilead Sciences to $170 From $160	MT
10-02	Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says	MT
09-10	HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating	MT
08-05	Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says	MT
08-05	Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126	MT
08-05	Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130	MT
08-05	RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating	MT
08-04	Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says	MT
07-28	Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating	MT
07-23	Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating	MT
07-21	Gilead Sciences Shares Fall After Downgrade From Leerink Partners	MT
07-21	Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike…
07-21	Leerink Partners Downgrades Gilead Sciences to Market Perform From Outperform, Adjusts PT to $127 From $146	MT
07-08	Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says	MT
07-08	Morgan Stanley Adjusts Price Target Gilead Sciences to $166 From $168, Maintains Overweight Rating	MT
07-07	Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157	MT
07-07	RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating	MT
07-06	Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow…
07-06	HSBC Upgrades Gilead Sciences to Buy From Hold, Adjusts Price Target to $155 From $133	MT
06-08	Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	GILEAD SCIENCES, INC.					+2.34%
	ELI LILLY AND COMPANY					+5.65%
	JOHNSON & JOHNSON					+9.33%
	ABBVIE INC.					-0.99%
	ROCHE HOLDING AG					-0.52%
	MERCK & CO., INC.					+8.56%
	NOVARTIS AG					-0.8%
	ASTRAZENECA PLC					+26.78%
	AMGEN INC.					-8.67%
	NOVO NORDISK A/S					+16.81%
	Average					+5.85%
	Weighted average by Cap.					+5.46%